Avacta Group PLC Avacta to Present at Investor Evening
November 13 2017 - 2:00AM
RNS Non-Regulatory
TIDMAVCT
Avacta Group PLC
13 November 2017
13 November 2017
Avacta Group plc
("Avacta", "the Group" or "the Company")
Avacta to Present at Investor Evening
Avacta Group plc (AIM: AVCT), the developer of Affimer(R)
biotherapeutics and reagents, is pleased to announce that its Chief
Executive Officer, Alastair Smith, will be presenting at an
investor evening hosted by Turner Pope Investments (TPI) Ltd. The
event will be held on 4 December 2017 in Mayfair, London W1 and
will commence at 5pm.
To register your interest, please email info@turnerpope.com or
call 0203 621 4121.
For further information from Avacta Group plc, please
contact:
Avacta Group plc Tel: +44 (0)
Alastair Smith, Chief Executive 844 414 0452
Officer www.avacta.com
Tony Gardiner, Chief Financial
Officer
finnCap Ltd Tel: +44 (0)
Geoff Nash / Giles Rolls - Nominated 207 220 0500
Adviser www.finncap.com
Tim Redfern / Alice Lane / Nikita
Jain - Corporate Broking
WG Partners Tel: +44 (0)
Nigel Birks / Nigel Barnes 203 705 9318
David Wilson / Claes Spang Tel: +44 (0)
203 705 9217
www.wgpartners.co.uk
Zyme Communications (Trade and Tel: +44 (0)7787
Regional Media) 502 947
Katie Odgaard katie.odgaard@zymecommunications.com
Yellow Jersey PR (Financial Media Tel: +44 (0)7764
and IR) 947137
Sarah Hollins avacta@yellowjerseypr.com
About Avacta Group plc (www.avacta.com)
Avacta's principal focus is on its proprietary Affimer(R)
technology which is a novel engineered alternative to antibodies
that has wide application in Life Sciences for diagnostics,
therapeutics and general research and development.
Antibodies dominate markets worth in excess of $50bn despite
their shortcomings. Affimer technology has been designed to address
many of these negative performance issues, principally; the time
taken to generate new antibodies, the reliance on an animal's
immune response, poor specificity in many cases, and batch to batch
variability. Affimer technology is based on a small protein that
can be quickly generated to bind with high specificity and affinity
to a wide range of protein targets.
Avacta has a pre-clinical biotech development programme with an
in-house focus on immuno-oncology and bleeding disorders as well as
partnered development programmes. Avacta is commercialising
non-therapeutic Affimer reagents through licensing to developers of
life sciences research tools and diagnostics.
To register for Avacta news alerts by email go to
www.avacta.com/investor-news-email-alerts
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAFSMFWAFWSESF
(END) Dow Jones Newswires
November 13, 2017 02:00 ET (07:00 GMT)
Avacta (LSE:AVCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avacta (LSE:AVCT)
Historical Stock Chart
From Apr 2023 to Apr 2024
